Papers - TANAKA Hisashi
-
The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Hiroaki Sakamoto, Hisashi Tanaka, Toshihiro Shiratori, Keisuke Baba, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka
Molecular and clinical oncology 10 ( 6 ) 610 - 614 2019.6
-
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka, Keisuke Baba, Toshihiro Shiratori, Hiroaki Sakamoto, Junichiro Tsuchiya, Hideyuki Nakagawa, Yukihiro Hasegawa, Hideo Yasugahira, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
Medical oncology (Northwood, London, England) 36 ( 6 ) 57 - 57 2019.5
-
Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).
Yusuke Okuma, Kei Morikawa, Hisashi Tanaka, Takuma Yokoyama, Hidetoshi Itani, Kazuya Horiuchi, Hideyuki Nakagawa, Nobumasa Takahashi, Akihiro Bessho, Kenzo Soejima, Kazuma Kishi, Akira Togashi, Yae Kanai, Koji Ueda, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki
Thoracic cancer 10 ( 2 ) 395 - 400 2019.2
-
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Keisuke Baba, Hisashi Tanaka, Hiroaki Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Sadatomo Tasaka
Thoracic cancer 10 ( 2 ) 369 - 372 2019.2
-
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Baba K, Tanaka H, Sakamoto H, Shiratori T, Tsuchiya J, Ishioka Y, Itoga M, Taima K, Tasaka S
Thorac Cancer 2019.1
-
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
Ryo Ko, Takehito Shukuya, Yusuke Okuma, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, Keisuke Azuma, Keiko Muraki, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Satoshi Morita, Kunihiko Kobayashi, Toshihiro Nukiwa, Kazuhisa Takahashi,
The oncologist 23 ( 10 ) 1210 - 1217 2018.10
-
脊髄炎，感覚性軸索型ニューロパチーを呈した傍腫瘍性神経症候群の1例
土屋純一郎，田中 寿志，當麻 景章 他
日本呼吸器学会誌 7 ( 4 ) 212 - 215 2018.7
-
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga, Yoshiko Ishioka, Hideyuki Nakagawa, Keisuke Baba, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka
Medical oncology (Northwood, London, England) 35 ( 3 ) 34 - 34 2018.2
-
A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
BMC cancer 17 ( 1 ) 683 - 683 2017.10
-
Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Kunihiko Nakamura, Yoshihito Tanaka, Masamichi Itoga, Shingo Takanashi, Ken Okumura
BMC research notes 9 ( 1 ) 173 - 173 2016.3
-
Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.
Hisashi Tanaka, Atsushi Horiike, Toshio Sakatani, Ryota Saito, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Takeshi Horai, Makoto Nishio
Anti-cancer drugs 26 ( 5 ) 573 - 578 2015.6
-
Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus.
Masamichi Itoga, Yuko Asari, Takeshi Morimoto, Kageaki Taima, Kunihiko Nakamura, Yoshihito Tanaka, Hisashi Tanaka, Shingo Takanashi, Hiroyuki Kayaba, Ken Okumura
BMC research notes 8 268 - 268 2015.6
-
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takeshi Horai, Makoto Nishio
Anticancer research 34 ( 4 ) 1975 - 1981 2014.4
-
The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.
Hisashi Tanaka, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Kunihiko Nakamura, Akihito Hayashi, Akira Kurose, Ken Okumura, Shingo Takanashi
OncoTargets and therapy 7 87 - 90 2013.12
-
Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma.
Hisashi Tanaka, Kiyoshi Tone, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Hideyuki Nakagawa, Shingo Takanashi, Ken Okumura, Akira Kurose
Lung cancer (Amsterdam, Netherlands) 80 ( 3 ) 289 - 292 2013.6
-
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Hisashi Tanaka, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Michiko Shimada, Akira Kurose, Shingo Takanashi, Ken Okumura
BMC cancer 12 558 - 558 2012.11